Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
16.5 (1y: +89%)
Market Cap 294.9 M P/E(ttm)
Enterprise Value 277.8 M P/B 13.36
RPRX- NAS (USA)
Repros Therapeutics, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$16.50
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry		 vs
history
Cash to Debt No Debt
RPRX's Cash to Debt is ranked higher than
59% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 46.63 vs. RPRX: No Debt )
RPRX' s 10-Year Cash to Debt Range
Min: 6.35   Max: No Debt
Current: No Debt
Equity to Asset 0.858
RPRX's Equity to Asset is ranked higher than
86% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. RPRX: 0.858 )
RPRX' s 10-Year Equity to Asset Range
Min: -0.11   Max: 0.98
Current: 0.86
-0.11
0.98
Interest Coverage No Debt
RPRX's Interest Coverage is ranked higher than
76% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 37.90 vs. RPRX: No Debt )
RPRX' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 1
Z-Score: 33.14
M-Score: -29.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -605566.70
RPRX's Operating margin (%) is ranked lower than
100% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -31.50 vs. RPRX: -605566.70 )
RPRX' s 10-Year Operating margin (%) Range
Min: -624550   Max: -101.1
Current: -605566.7
-624550
-101.1
Net-margin (%) -605567
RPRX's Net-margin (%) is ranked lower than
100% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -29.90 vs. RPRX: -605567 )
RPRX' s 10-Year Net-margin (%) Range
Min: -624550   Max: -35.9
Current: -605567
-624550
-35.9
ROE (%) -78.9
RPRX's ROE (%) is ranked lower than
82% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. RPRX: -78.9 )
RPRX' s 10-Year ROE (%) Range
Min: -4845.9   Max: -2.7
Current: -78.9
-4845.9
-2.7
ROA (%) -67.7
RPRX's ROA (%) is ranked lower than
85% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. RPRX: -67.7 )
RPRX' s 10-Year ROA (%) Range
Min: -920.1   Max: -2.3
Current: -67.7
-920.1
-2.3
Revenue Growth (%) -100
RPRX's Revenue Growth (%) is ranked lower than
98% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RPRX: -100 )
RPRX' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 118.3
Current: -100
-100
118.3
EBITDA Growth (%) -34.2
RPRX's EBITDA Growth (%) is ranked lower than
93% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RPRX: -34.2 )
RPRX' s 10-Year EBITDA Growth (%) Range
Min: -39.6   Max: 49.4
Current: -34.2
-39.6
49.4
EPS Growth (%) -34.2
RPRX's EPS Growth (%) is ranked lower than
93% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RPRX: -34.2 )
RPRX' s 10-Year EPS Growth (%) Range
Min: -39.3   Max: 79.1
Current: -34.2
-39.3
79.1
ยป RPRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

RPRX Guru Trades in Q2 2012

Jim Simons 101,700 sh (New)
» More
Q3 2012

RPRX Guru Trades in Q3 2012

Jim Simons 38,888 sh (-61.76%)
» More
Q4 2012

RPRX Guru Trades in Q4 2012

Steven Cohen 55,572 sh (New)
Jim Simons Sold Out
» More
Q1 2013

RPRX Guru Trades in Q1 2013

Steven Cohen 1,275,000 sh (+2194.32%)
» More
» Details

Insider Trades

Latest Guru Trades with RPRX



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 13.36
RPRX's P/B is ranked lower than
86% of the 359 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. RPRX: 13.36 )
RPRX' s 10-Year P/B Range
Min: 0.4   Max: 34.4
Current: 13.36
0.4
34.4
EV-to-EBIT -13.89
RPRX's EV-to-EBIT is ranked lower than
92% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. RPRX: -13.89 )
RPRX' s 10-Year EV-to-EBIT Range
Min: 64   Max: 202.4
Current: -13.89
64
202.4

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 15
RPRX's Price/Net Cash is ranked lower than
63% of the 189 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. RPRX: 15 )
RPRX' s 10-Year Price/Net Cash Range
Min: 0.5   Max: 47.6
Current: 15
0.5
47.6
Price/Net Current Asset Value 222.7
RPRX's Price/Net Current Asset Value is ranked lower than
88% of the 313 Companies
in the Global Biotechnology industry.

( Industry Median: 41.90 vs. RPRX: 222.7 )
RPRX' s 10-Year Price/Net Current Asset Value Range
Min: 1.2   Max: 241
Current: 222.7
1.2
241
Price/Tangible Book 13.4
RPRX's Price/Tangible Book is ranked lower than
78% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. RPRX: 13.4 )
RPRX' s 10-Year Price/Tangible Book Range
Min: 0.4   Max: 33.9
Current: 13.4
0.4
33.9
Earnings Yield (Greenblatt) 1169.40
RPRX's Earnings Yield (Greenblatt) is ranked higher than
99% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. RPRX: 1169.40 )
RPRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 1.6
Current: 1169.4
0.5
1.6
Forward Rate of Return (Yacktman) -43.25
RPRX's Forward Rate of Return (Yacktman) is ranked lower than
86% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RPRX: -43.25 )
RPRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -86.5   Max: -41.5
Current: -43.25
-86.5
-41.5

Business Description

Repros Therapeutics Inc. was organized on August 20, 1987. It is a development stage biopharmaceutical Company focusing on the development of oral small molecule drugs for major unmet medical needs. The Company's current product pipeline consists of: Proellex for female reproductive health and Androxal for male reproductive health. The company's lead drug, Proellex, is a selective blocker of the progesterone receptor. It is developing Proellex for three indications: anemia associated with uterine fibroids, chronic treatment of symptoms associated with uterine fibroids and chronic treatment of symptoms associated with endometriosis. The company's second product candidate, Androxal is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. The company was previously developing Androxal in the United States to treat testosterone deficiency due to secondary hypogonadism by restoring normal testosterone production in males with functional testes and diminished pituitary function, a common condition in the aging male. The company is also continuing limited out-licensing efforts for its phentolamine-based product candidates, including VASOMAX, which had previously been approved for marketing in several countries in Latin America for the treatment of male erectile dysfunction under the brand name, Z-Max. VASOMAX is currently on partial clinical hold in the U.S. The Company would continue to explore corporate partnering opportunities for assistance in the clinical development funding and commercialization of its products.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:ZONN.Germany
ยป More Articles for RPRX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 
Repros Therapeutics Inc. (RPRX) CEO Joseph Podolski buys 4,000 Shares Mar 05 2009 
Weekly CEO Buys Highlight: Medtox Scientific Inc., Provident Bankshares Corp., Escalade Inc., Repros Apr 25 2008 

More From Our Partners
Repros to Conduct Phase IIb Trial - Analyst Blog May 23 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial